Drug firm Lupin has announced its results for the quarter ended September 2010. It has reported consolidated net profit at Rs 215 crore as against Rs 160 crore, a growth of 34.375% on year-on-year basis.
Consolidated net sales jumped 26.01% to Rs 1,405 crore from Rs 1,115 crore.
The company's trailing 12-month (TTM) EPS was at Rs 14.06 per share (June, 2010). The stock's price-to-earnings (P/E) ratio was 31.97. The latest book value of the company is Rs 56.77 per share.
At current value, the price-to-book value of the company was 7.92. The dividend yield of the company was 0.6%.
The stock's price-to-earnings (P/E) ratio stands at 32.04 on (NSE).
Source: www.moneycontrol.com
Thanks,
Gaurav Agarwal
Head Dealer
DENIP Consultants Pvt Ltd
No comments:
Post a Comment